PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue the Phase 1 study with the goal of advancing to Phase 2 early next year. The tumor-suppressing protein p53 has long been considered …
Adagrasib Shows Promise in Difficult-to-Treat Lung Cancer Subset
When given as a single-agent (not with any other drugs), adagrasib led to promising outcomes for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to results from part of the phase 1/2 KRYSTAL-1 clinical trial that were presented at the 2022 American Society of Clinical Oncology Annual Meeting. At the meeting, Dr. Alexander I. Spira, co-director of Virginia Cancer …
NEXT Oncology Enrolls First Patient in Madrid Phase I Clinical Research Center
When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer (TNBC) with an anti-drug conjugate used in …
NEXT Oncology Partners with Spanish Hospital System to Open Two Phase I Clinical Trial Centers
NEXT Oncology, founded by internationally known cancer researcher Dr. Anthony Tolcher, has entered into an agreement with the Quirónsalud Group to open two new phase I clinical trial centers in Spain. The venture increases global access to new agents and anticancer therapies for cancer patients. View the full article at Let Life Happen
Understanding your risk for breast cancer key to getting treatment
A local oncologist talks about a group that’s at higher risk of dying from breast cancer. View the video at KSAT.com
Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team
Sharon Wilks joined NEXT Oncology’s phase I clinical investigation team, bringing more than 30 years of research and clinical experience to the practice. View the full article at the Cancer Letter
NEXT Oncology Partners with Spanish Hospital System to Open Two Phase I Clinical Trial Centers
NEXT Oncology entered into an agreement with the Quirónsalud Group to open two new phase I clinical trial centers in Spain. View the full article at Cancer Letter
Quirónsalud launches two new phase I clinical trial units in Madrid and Barcelona
El Grupo Quirónsalud ha puesto en marcha dos nuevas unidades de ensayos clínicos de fase I gracias al acuerdo alcanzado con NEXT Oncology, empresa estadounidense líder en el desarrollo de este tipo de ensayos creará en Europa. The Quirónsalud Group has launched two new phase I clinical trial units thanks to the agreement reached with NEXT Oncology, a leading American company in the development of …
Next Oncology Expends Phase I Program with Virginia Cancer Specialists Partnership
For the latest installment of the Inside the Practice Segment of the Medical World News® broadcast, CancerNetwork® spoke with Anthony W. Tolcher, MD, co-founder of NEXT Oncology and a medical oncologist at Texas Oncology, as well as Alexander I. Spira, MD, PhD, director of Virginia Cancer Specialists Research Institute and the Phase I Trial Program, to discuss their new partnership and how …
Medical World News® Inside the Practice: CancerNetwork® With Anthony W. Tolcher, MD, and Alexander I. Spira, MD, PhD, on Expand Access to Phase 1 Cancer Trials
For the latest installment of the Inside the Practice Segment of the Medical World News® broadcast, CancerNetwork® spoke with Anthony W. Tolcher, MD, co-founder of NEXT Oncology and a mMedical oOncologist at Texas Oncology, as well as Alexander I. Spira, MD, PhD, Medical Oncologist and dDirector of Virginia Cancer Specialists Research Institute and the Phase I Trial Program, to discuss their new …